Pfizer expands lease agreement with Kendall Square for research facility
With this expansion, Pfizer has leased the complete 500,000ft² at 610 Main Street in Kendall Square and this space will continue to house the research and development (R&D)
With this expansion, Pfizer has leased the complete 500,000ft² at 610 Main Street in Kendall Square and this space will continue to house the research and development (R&D)
With the in cell factory technology, living cells can be controlled and manipulated to make specific proteins with therapeutic benefits. Under the deal, MedImmune will provide funding and
The Yokebe is expected to generate about €30m in full year 2015 net sales. Yokebe comes in a shake/liquid form and is marketed within the ‘meal replacement’ category.
Ofatumumab is designed to target the CD20 molecule found on the surface of CLL cells and normal B lymphocytes. The sBLA, which was submitted by Novartis under Genmab’s
Iluvien is Alimera’s sustained release intravitreal implant designed for the treatment of diabetic macular edema (DME). Currently, Iluvien is not approved for sale in Canada. Iluvien (fluocinolone acetonide
The company said that BMS-663068 is an oral prodrug of the molecule BMS-626529 and first-in-class HIV-1 attachment inhibitor. BMS-663068 is designed to work differently than entry inhibitors, a
Dosing in this multi-center, open-label, dose-escalation trial has been carried out by the University of Virginia School of Medicine. The company is conducting the trial in collaboration with
The company said that ISIS-HTT is the first therapy to enter clinical development that is designed to directly target the cause of the disease by reducing the production
MGB-BP-3 is an antibiotic that has been shown to be active against a broad range of important multi-resistant Gram-positive pathogens. The company has developed the oral formulation of
The study will use Forge’s expertise and intellectual property in the field of metalloprotein inhibitor discovery, while the company will receive funding support from JRD. Forge Therapeutics CEO